CD44 POLYMORPHISMS PREDICT CLINICAL OUTCOME IN PATIENTS WITH GASTRIC CANCER

• 1. HDS在预测胃癌患者的预后、指导术后辅助化疗和预测免疫治疗疗效中的应用 [P] . 中国专利： CN114134232A . 2022-03-04
• 2. 多态性检测用探针、多态性检测方法、药效评价方法、疾病预测方法以及多态性检测用试剂盒 [P] . 中国专利： CN102766681B . 2015.08.19
• 3. POLYMORPHISMS TOLL LIKE RECEPTOR GENES PREDICTS CLINICAL OUTCOMES OF COLORECTAL CANCER PATIENTS [P] . 美国专利： US2019161803A1 . 2019-05-30

  机译： 象受体基因多态性预测大肠癌患者的临床结果

• 4. POLYMORPHISMS IN CACHEXIA PREDICT CLINICAL OUTCOMES OF COLORECTAL CANCER PATIENTS RECEIVING IRINOTECAN AND BEVACIZUMAB [P] . 美国专利： US2018311347A1 . 2018-11-01

  机译： 多态性可预测接受伊诺替康和贝伐珠单抗治疗的大肠癌患者的临床结果

• 5. POLYMORPHISMS TOLL LIKE RECEPTOR GENES PREDICTS CLINICAL OUTCOMES OF COLORECTAL CANCER PATIENTS [P] . 世界知识产权组织专利： WO2017185063A1 . 2017-10-26

  机译： 象受体基因多态性预测大肠癌患者的临床结果

• 1. LRP5 polymorphism-A potential predictor of the clinical outcome in advanced gastric cancer patients treated with EOF regimen [J] . Xin Liu, Ming-Zhu Huang, Zhi-Yu Chen, 中国癌症研究（英文版） . 2014,第004期
• 2. Association of Two CD44 Polymorphisms with Clinical Outcomes of Gastric Cancer Patients [J] . Seyed Mohammadreza Bitaraf, Reihaneh Alsadat Mahmoudian, Mohammadreza Abbaszadegan, Asian Pacific Journal of Cancer Prevention . 2018,第5期
• 3. The relationship of Vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer [J] . Sung Yong Oh, Hyuk-Chan Kwon, Sung Hyun Kim, BMC Cancer . 2013,第1期
• 4. The relationship of Vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer [J] . Sung Yong Oh, Hyuk-Chan Kwon, Sung Hyun Kim, BMC Cancer . 2013,第1期
• 5. Collaborative Clustering Of Subjects And Radiomic Features For Predicting Clinical Outcomes Of Rectal Cancer Patients [C] . Hangfan Liu, Hongming Li, Pamela Boimel, IEEE International Symposium on Biomedical Imaging . 2019
• 6. Clinical and Economic Outcomes for Gastric Cancer Patients Treated with Gastrectomy at Centres with and without Cancer Surgery Designation in Ontario [D] . Jeong, Yunni . 2019
• 7. Association of Two CD44 Polymorphisms with Clinical Outcomes of Gastric Cancer Patients [O] . Seyed Mohammadreza Bitaraf, Reihaneh Alsadat Mahmoudian, Mohammadreza Abbaszadegan, 2018
• 8. Association of two polymorphism of CD44 molecule with clinical outcome of gastric cancer patients [O] . Reza Bitaraf Seyyed Mohammad, Abbaszadegan Mohammad Reza, Meybodi Anahita Mohseni, 2015

• 1. Polymorphisms of ERCC1, XPD, XRCC1 and XPG Predict Clinical Outcome in Advanced Gastric Cancer Patients Receiving Oxaliplatin-Based Chemotherapy in Chinese Population [J] . Jian Jiang ,Jun Liang ,Ruyong Yao . 临床肿瘤和癌症研究 . 2009,第005期
• 2. ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer [J] . Zhao-Hui Huang ,Dong Hua ,Xiang Du . 世界胃肠病学杂志：英文版 . 2008,第41期
• 3. TT genotype of GNAS1 T393C polymorphism predicts better outcome of advanced non-small cell lung cancer patients [J] . Hong-Yun Gong ,Wei-Guo Hu ,Xiu-Ling Wang . 世界胃肠肿瘤学杂志：英文版（电子版） . 2014,第12期
• 4. Blood parameters score predicts long-term outcomes in stage Ⅱ-Ⅲ gastric cancer patients [J] . Jian-Xian Lin ,Yi-Hui Tang ,Jia-Bin Wang . 世界胃肠病学杂志：英文版 . 2019,第41期
• 5. 亚甲基四氢叶酸还原酶C667T基因多态性对以5-FU为基础化疗的晚期胃癌患者生存期的影响 [C] . 季枚 ,蒋敬庭 ,吴昌平 . 第十五届全国临床肿瘤学大会暨2012年CSCO学术年会 . 2012
• 6. 晚期胃癌患者外周血XPD、XPA、XRCC1、GSTP1基因多态性对以奥沙利铂为基础的化疗方案临床疗效及生存的预测作用 [A] . 刘同欣 . 2011